A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

A Howard County man is suing Novo Nordisk, alleging Ozempic caused him to go blind after using the drug to treat diabetes. He seeks damages in court.

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.

Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk A/S, whose diabetes and ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Ozempic and similar weight loss drugs are currently at the center of multidistrict litigation over claims that the drugs ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...